With focus firmly fixed on the future, Johnson & Johnson have confirmed payment of $3.4bn for California-based Auris, a leader in the surgical robotics market.
Auris Health is a privately held developer of robotic technologies that was initially focused on lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. Once the deal itself closes, there will be further opportunity of another $2.65bn once various milestones are reached.
This acquisition will accelerate Johnson & Johnson’s entry into robotics with potential for growth and expansion into other interventional applications.
“In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer,” said Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson.
“We believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes.”
Some analysts have seen J&J increasing its share value in the surgical robotics market and are now predicting it could reach a total value of around $12bn by 2025.
Frederic Moll, M.D., CEO and Founder of Auris Health, said: “We’re thrilled to be joining Johnson & Johnson to help push the boundaries of what is possible in medical robotics and improve the lives of patients across the globe.
“Together, we will be able to dramatically accelerate our collective product innovation to develop new interventional solutions that redefine optimal patient outcomes.”